With the discovery of immune checkpoint inhibitors, increased PD-L1 expression has been proposed as a predictive marker for increased responses (18), which makes miR-155 a suitable candidate for exploration in breast cancer immunotherapy. This evidence concerns the gene CD274 and breast carcinoma.